VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
Top Cited Papers
Open Access
- 4 April 2005
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 201 (7), 1089-1099
- https://doi.org/10.1084/jem.20041896
Abstract
The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood. Vascular endothelial growth factor (VEGF)-A plays a principle role in tumor progression and angiogenesis; however, its role in tumor-associated lymphangiogenesis and lymphatic metastasis has remained unclear. We created transgenic mice that overexpress VEGF-A and green fluorescent protein specifically in the skin, and subjected them to a standard chemically-induced skin carcinogenesis regimen. We found that VEGF-A not only strongly promotes multistep skin carcinogenesis, but also induces active proliferation of VEGF receptor-2–expressing tumor-associated lymphatic vessels as well as tumor metastasis to the sentinel and distant lymph nodes. The lymphangiogenic activity of VEGF-A–expressing tumor cells was maintained within metastasis-containing lymph nodes. The most surprising finding of our study was that even before metastasizing, VEGF-A–overexpressing primary tumors induced sentinel lymph node lymphangiogenesis. This suggests that primary tumors might begin preparing their future metastatic site by producing lymphangiogenic factors that mediate their efficient transport to sentinel lymph nodes. This newly identified mechanism of inducing lymph node lymphangiogenesis likely contributes to tumor metastasis, and therefore, represents a new therapeutic target for advanced cancer and/or for the prevention of metastasis.Keywords
This publication has 39 references indexed in Scilit:
- Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasiaBlood, 2004
- VEGF‐A promotes tissue repair‐associated lymphatic vessel formation via VEGFR‐2 and the α1β1 and α2β1 integrinsThe FASEB Journal, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic miceOncogene, 2002
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- The Formation of Lymphatic Vessels and Its Importance in the Setting of MalignancyThe Journal of Experimental Medicine, 2002
- The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculatureGenes & Development, 2002
- Mouse LYVE-1 Is an Endocytic Receptor for Hyaluronan in Lymphatic EndotheliumJournal of Biological Chemistry, 2001
- Cytokine Regulation of Proliferation and ICAM-1 Expression of Human Dermal Microvascular Endothelial Cells In VitroJournal of Investigative Dermatology, 1992